Hikma bring in new CSO
pharmafile | January 16, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Hikma, biotech, drugs, pharma, pharmaceutical
Hikma Pharmaceuticals has announced that Surendera Tyagi is being brought in to join the company as Group Chief Scientific Officer and Global Head of R&D. The company revealed that Tyagi’s principal role will be to inject some life into the group’s non-injectables business during his first year with Hikma.
Tyagi joins Hikma after having worked at Fresenius for over decade, taking on various roles during that period. He began his career as CSO of Fresenius’ Oncology unit before moving onto becoming Executive Vice President at the same unit and reaching his last position as Senior Vice President of the US division of the company. Prior to Fresenius, he also held roles at Abbot for over a decade and at Shwarz Pharma.
He will be tasked with using this experience to turn around Hikma’s fortunes, after the company took a serious hit alongside a weakening generics market – in a similar fashion to the biggest player in the market, Teva. As well as broader generics troubles, a more specific issue for the company is its problem in bringing a generic equivalent to GSK’s Advair.
It is expected that Hikma will now try to strengthen its own R&D efforts to weather the difficulties in the generics market, with Tyagi at the helm.
“I am delighted to be joining Hikma at this exciting time in the company’s journey, leading such an important function,” said Tyagi. “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share. I look forward to accelerating their R&D efforts by advancing and expanding their pipeline, leveraging Hikma’s highly experienced and talented R&D team.”
“Surendera is an outstanding scientist with a proven track record of leading research and development in some of the world’s largest and most successful pharmaceutical organizations,” said Saïd Darwazah, Chairman and Chief Executive Officer, Hikma. “Research and Innovation is one of our five pillars for growth and the appointment of Surendera is a significant step forward in executing on this strategy. We are very excited for Surendera to be joining us and accelerating our ability to develop novel ways to improve the health of people around the world.”
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …